elgx secur equiti financ relief debt
oblig clear path ahead updat pt
endologix announc multi-part financi transact includ
equiti rais exchang bulk convert
note convert note amend exist
credit facil agreement taken togeth transact necessari
help balanc sheet near term also bring signific equiti
dilut calcul result almost increas share
outstand next quarter doubl share count
end feel benefit investor near-term
financ overhang resolv reduc risk remain concern
elgx long-term prospect revis pre-revers stock split
pt use sum-of-the-part valuat assign revenu
multipl core busi valuat nellix
busi chanc posit data
confirmatori studi endologix need rais capit multipl
time next year decid stay independ
compani mind think valu deriv
sharehold put compani sale posit nellix data
think acquir would pay least core revenu
equiti rais convert note exchang revis
facil agreement clearli posit give elgx much-need
breath room allow debt payoff continu oper
continu think nellix data confirmatori
studi key elgx futur data strong think elgx
becom attract acquisit target
valuat revis pt base sum-of-
the-part adjust revers stock split equiti rais
debt restructur risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
make numer chang elgx model includ roll
estim updat balanc sheet cash flow statement
file adjust share count revers stock split march add
net proce april equiti financ adjust
share count transact also adjust share count debt
balanc mandatori convers senior note start
may continu month also reduc convert
note balanc debt extinguish assum
note facil payment paid
adjust share count debt balanc mandatori
convers facil agreement start april
continu month model voluntari convers sinc
depend specif share price requir
guarante model equiti rais earli
adjust project interest payment new convert note
semi-annu payment start octob also slightli increas
revenu pre-announce previous
model revenu adjust loss per
share forecast revenu adj lp
project revenu adj lp
bpsnmebit bpsnmsourc btig estim compani filingsnewold chang
endologix rate buy pt base sum-of-the-part
valuat assign multipl core busi valuat
nellix assum chanc good data potenti
elgx acquir also month revenu estim
multipl slower-grow small- mid-cap med-tech peer
discount feel warrant due signific debt load risk
around compani turnaround anticip data nellix trial
risk rate price target includ salesforc attrit signific
neg impact field safeti notic product recal nellix never
launch slow significantli europ competit
turnov potenti futur need capit fda
comp tabl small- mid-cap med-tech compani
ntm chanc posit nellix medicalwmginot factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
elgx incom etot y/i sale clinic market opex acq oper incom incom tax incom net incom share net incom oper expens btig estim compani report
elgx revenu esal geographi unit y/i y/i south america mexico y/i y/i y/i product y/i clinic specialist unit y/i revenu per us rep y/i growth revenue per us rep y/i revenu per eu rep y/i growth revenue per ou rep y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
